key: cord-0023342-4sgts1qv
authors: Romano, Ciro; Esposito, Sergio; Donnarumma, Giovanna; Marrone, Aldo
title: Authors’ response
date: 2021-11-23
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2021.09.023
sha: 79a3c05869d4f7d642c23c7b70abe3ba8fa538fa
doc_id: 23342
cord_uid: 4sgts1qv

nan

Messenger RNA vaccines and neutralizing anti−severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency

We would like to share our ideas on the article entitled "Detection of neutralizing anti−severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines." 1 Romano et al 1 concluded that "CVID patients must be included in COVID-19 vaccination programs because of the ability of mRNA vaccines to safely induce production of neutralizing antibodies in this category of patients." Given that Romano et al 1 noted that the production of neutralizing antibodies did not mean protection, it is, therefore, necessary to have further studies for confirmation on the advantage of vaccines. Whether the messenger RNA (mRNA) can result in unwanted immunologic problems in a common variable immunodeficiency (CVID) case is also another important question. An association between CVID and autoimmunity was proposed. 2, 3 There are many reports on the possible association between mRNA COVID-19 vaccine and autoimmunity generation. 4 A careful risk and benefit evaluation is needed for making any recommendation on using the mRNA COVID-19 vaccine among CVID cases. 

We understand the concerns expressed by Drs Mungmunpuntipantip and Wiwanitkit regarding the efficacy and safety of messenger (m)RNA vaccines in patients with common variable immunodeficiency (CVID); however, we still strongly stick to the conclusions expressed in our report. 1 With regard to efficacy, the aim of our study was to evaluate whether patients with CVID could generate neutralizing antibodies against severe acute respiratory syndrome coronavirus 2, and all but 1 actually did. 1 Clearly, as already mentioned in the article, evaluation of the clinical significance of these antibodies (ie, protection against severe manifestations of coronavirus disease 2019 [COVID-19] and death) requires further studies. 1 Nevertheless, it should not be overlooked that vaccine-induced cell-mediated immunity may as well contribute to vaccination efficacy. 2 Therefore, prediction of vaccination efficacy should not be solely anticipated on the basis of antispike antibody titers. Long-term adverse effects of COVID-19 vaccination are unknown across all categories of subjects being immunized; conversely, short-term adverse effects are generally mild and easily managed. 3, 4 Our patients with CVID have been followed up for more than 6 months since having completed the 2dosage mRNA vaccine schedule, and none of them have developed or had flare-ups of autoimmune or other long-term inflammatory conditions; other studies have reported reassuring safety data as well. 2, 5, 6 Furthermore, patients with rheumatologic diseases who have a myriad of autoimmune conditions have been thus far safely vaccinated with mRNA vaccines, with no apparent impact on disease activity and no further safety concerns in the short term. 7, 8 Severe adverse events, albeit rare, may nonetheless occur after vaccination, regardless of preexisting medical conditions. In any case, caution should be exercised in interpreting flare-ups of autoimmune diseases

Detection of neutralizing antisevere acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with mRNA vaccines

Autoimmunity in common variable immunodeficiency

Common variable immune deficiency and autoimmunity

Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases

Detection of neutralizing antisevere acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines

Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity

Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine

Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase

Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency

Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity [e-pub ahead of print

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort